Dose Proportionality of Linagliptin in Healthy Volunteers

Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau up to 168 hours, Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval tau up to 168 hours and 1 more. Started Jul 2009; status: completed.